Header Logo

Connection

William Hildebrand to Antibody Specificity

This is a "connection" page, showing publications William Hildebrand has written about Antibody Specificity.
Connection Strength

0.692
  1. Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J Immunol Methods. 2006 Jul 31; 314(1-2):38-53.
    View in: PubMed
    Score: 0.258
  2. Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late. J Immunol. 2016 05 15; 196(10):4263-73.
    View in: PubMed
    Score: 0.127
  3. Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer. Mol Cancer Ther. 2016 Feb; 15(2):313-22.
    View in: PubMed
    Score: 0.125
  4. Expanding the targets available to therapeutic antibodies via novel disease-specific markers. Int Rev Immunol. 2011 Oct-Dec; 30(5-6):312-27.
    View in: PubMed
    Score: 0.093
  5. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods. 2007 Jan 10; 318(1-2):47-58.
    View in: PubMed
    Score: 0.066
  6. An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer. J Immunol. 2011 Jun 01; 186(11):6607-16.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.